Literature DB >> 7504567

Changing trends in the management of extrahepatic cholangiocarcinoma.

C M Guthrie1, G Haddock, A C De Beaux, O J Garden, D C Carter.   

Abstract

A series of 107 patients with cholangiocarcinoma diagnosed between January 1980 and December 1991 is reported. Changing patterns of investigation and treatment in the periods 1980-1985 and 1986-1991 are analysed. There was a decrease in the use of percutaneous transhepatic cholangiography in the second period (86 versus 51 per cent of patients) but increased use of endoscopic retrograde cholangiography (19 versus 71 per cent) and computed tomography (8 versus 59 per cent). The overall resectability rate (17 per cent) was similar to those of other reported series but greater in the second period (8 versus 21 per cent). Palliation by endoscopic and percutaneous stenting was associated with a high incidence of recurrent cholangitis (55 per cent) and jaundice (35 per cent). During the second 6-year period, more effective palliation was achieved by segment III cholangiojejunostomy with a lower incidence of recurrent cholangitis (19 per cent) and jaundice (19 per cent). Overall prognosis for patients with this condition is grim and efforts must usually be aimed at providing the most appropriate palliation.

Entities:  

Mesh:

Year:  1993        PMID: 7504567     DOI: 10.1002/bjs.1800801128

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  12 in total

1.  Changing trends of surgical treatment of hilar bile duct cancer: clinical and experimental perspectives.

Authors:  Zhi-Qiang Huang; Ning-Xin Zhou; Da-Dong Wang; Jian-Guo Lu; Ming-Yi Chen
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

2.  Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Yasuo Hayashidani; Takeshi Sudo; Hiroki Ohge; Taijiro Sueda
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

3.  Improved post-transplant survival in the United States for patients with cholangiocarcinoma after 2000.

Authors:  Reena J Salgia; Amit G Singal; Sherry Fu; Shawn Pelletier; Jorge A Marrero
Journal:  Dig Dis Sci       Date:  2013-03-16       Impact factor: 3.199

Review 4.  Perihilar cholangiocarcinoma: Current therapy.

Authors:  Wei Zhang; Lu-Nan Yan
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

Review 5.  Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection.

Authors:  T Kosuge; J Yamamoto; K Shimada; S Yamasaki; M Makuuchi
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

Review 6.  Surgical treatment in proximal bile duct cancer. A single-center experience.

Authors:  R Pichlmayr; A Weimann; J Klempnauer; K J Oldhafer; H Maschek; G Tusch; B Ringe
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

7.  Air cholangiogram is not inferior to dye cholangiogram for malignant hilar biliary obstruction: a randomized study of efficacy and safety.

Authors:  Randhir Sud; Rajesh Puri; Narendra S Choudhary; Ashish Mehta; Parvesh Kumar Jain
Journal:  Indian J Gastroenterol       Date:  2015-01-24

8.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

9.  Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasuo Hayashidani; Yasushi Hashimoto; Hiroaki Nakamura; Akira Nakashima; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2009-05-07       Impact factor: 3.452

10.  Guidelines for palliative surgery of cholangiocarcinoma.

Authors:  H Witzigmann; H Lang; H Lauer
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.